Clinical Trial Update: A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating APX005M in combination with nivolumab and ipilimumab in treatment-naïve patients with advanced melanoma or renal cell carcinoma; the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• APX005M
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Yale University | Conditions: Advanced Melanoma, Renal Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING